The company reported a net loss of $7.36 million for 2025, compared to a net loss of $5.81 million in 2024. The loss from operations increased to $7.19 million, primarily due to lower license and milestone revenue, despite a reduction in general and administrative expenses. Dyadic's cash position as of December 31, 2025, stood at approximately $8.6 million, a decrease from $9.29 million in the prior year.
In terms of operational developments, Dyadic highlighted several strategic collaborations and product launches. The commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals was noted, with Dyadic set to receive a share of profits from product sales. Additionally, the company expanded its collaboration with Fermbox Bio and signed an OEM distribution agreement with IBT Bioservices to commercialize its recombinant DNase I and transferrin products.
Despite the challenges faced in 2025, Dyadic remains committed to accelerating the commercialization of its expanding portfolio of animal-free proteins and enzymes. The company aims to leverage its microbial production platforms to generate recurring revenue streams and enhance its market presence across various sectors, including life sciences, food and nutrition, and bio-industrial markets. The leadership expressed optimism about future growth opportunities and the potential for increased product offerings and partnerships.
